Up­dat­ed: Pfiz­er drops half of par­tic­i­pants from Ly­me tri­al af­ter say­ing re­search con­trac­tor broke rules

Pfiz­er is re­mov­ing about sev­er­al thou­sand US par­tic­i­pants from a Phase III Ly­me dis­ease tri­al be­cause a con­trac­tor run­ning some clin­i­cal sites vi­o­lat­ed qual­i­ty stan­dards, the drug­mak­er and its French biotech part­ner Val­ne­va said Fri­day.

Pfiz­er said that about 7,000 peo­ple had been en­rolled so far, and half will be re­moved. They’re be­ing pulled be­cause of vi­o­la­tions of Good Clin­i­cal Prac­tice (GCP) rules, which re­fer to the eth­i­cal and sci­en­tif­ic stan­dards for sites, the com­pa­nies said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER